BTK degradation as a novel therapeutic strategy for relapsed CNS lymphoma

Tafasitamab at the blood-brain barrier: exploring this agent for the treatment of CNS lymphoma

A Phase I/II trial exploring tafasitamab plus lenalidomide in relapsed CNS lymphoma

human geography by james rubenstein

The prognostic significance and therapeutic potential of the TLR 7/8 pathway in CNS lymphomas

Exploring therapy-driven evolution and genetic heterogeneity in CNS lymphomas

Identification of genomic biomarkers of disease progression & survival in primary CNS lymphoma